Abstract
This in vitro study demonstrates the comparative anti-inflammatory effects of rosiglitazone and 15d-PGJ(2) in endometriosis and provides evidence for exploitation of peroxisome proliferator-activated receptor-γ as a therapeutic target.
Copyright © 2011 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Anti-Inflammatory Agents / pharmacology*
-
Biopsy
-
Case-Control Studies
-
Cells, Cultured
-
Drug Evaluation, Preclinical
-
Endometriosis / pathology
-
Endometrium / drug effects*
-
Endometrium / metabolism
-
Endometrium / pathology
-
Endometrium / physiology
-
Female
-
Gene Expression / drug effects*
-
Humans
-
Ligands
-
Lipopolysaccharides / pharmacology*
-
PPAR gamma / agonists*
-
PPAR gamma / genetics
-
PPAR gamma / metabolism
-
Prostaglandin D2 / pharmacology
-
Rosiglitazone
-
Stromal Cells / drug effects*
-
Stromal Cells / metabolism
-
Stromal Cells / pathology
-
Stromal Cells / physiology
-
Thiazolidinediones / pharmacology
-
Uterine Diseases / pathology
Substances
-
Anti-Inflammatory Agents
-
Ligands
-
Lipopolysaccharides
-
PPAR gamma
-
Thiazolidinediones
-
Rosiglitazone
-
Prostaglandin D2